Sandip Kapadia to sell 3,746 Harmony Biosciences (NASDAQ: HRMY) shares

Rhea-AI Filing Summary

A holder has filed a notice to sell 3,746 shares of Harmony Biosciences common stock (HRMY). The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 01/26/2026 on the NASDAQ market. These shares come from restricted stock units acquired from the issuer on 01/24/2026.

The notice also lists recent activity under a Rule 10b5-1 trading plan for Sandip Kapadia. Over the past three months, there were sales of 20,961 shares for $752,833.18 on 01/15/2026, 20,000 shares for $790,896.00 on 12/05/2025, and 3,427 shares for $119,945.00 on 11/21/2025. The filer represents that they are not aware of undisclosed material adverse information about Harmony Biosciences.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3746	137927.72	57596358	01/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/24/2026	Restricted Stock Units	Issuer			3746	01/24/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SANDIP KAPADIA 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	01/15/2026	20961	752833.18
10b5-1 Sales for SANDIP KAPADIA 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	12/05/2025	20000	790896.00
10b5-1 Sales for SANDIP KAPADIA 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462	Common	11/21/2025	3427	119945.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing for HRMY disclose?

The filing discloses a planned sale of 3,746 shares of Harmony Biosciences (HRMY) common stock, to be sold through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on the NASDAQ exchange.

Who is associated with the Harmony Biosciences shares being sold?

The filing identifies Sandip Kapadia in connection with recent Rule 10b5-1 sales of Harmony Biosciences common stock, and lists those sales in the past three months.

How many Harmony Biosciences shares are planned for sale under this notice?

The notice covers a proposed sale of 3,746 shares of Harmony Biosciences common stock, with an indicated aggregate market value of $137,927.72 and 57,596,358 shares outstanding referenced as a baseline figure.

What is the source of the 3,746 HRMY shares to be sold?

The 3,746 shares are shown as derived from restricted stock units that were acquired from the issuer on 01/24/2026, with the nature of payment listed as N/A.

What recent 10b5-1 sales for Sandip Kapadia are disclosed?

The filing lists three 10b5-1 sales of Harmony Biosciences common stock for Sandip Kapadia: 20,961 shares for $752,833.18 on 01/15/2026, 20,000 shares for $790,896.00 on 12/05/2025, and 3,427 shares for $119,945.00 on 11/21/2025.

What representation does the seller make about Harmony Biosciences information?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about the current or prospective operations of Harmony Biosciences that has not been publicly disclosed.